Trovagene,Inc. (NASDAQ:TROV) Files An 8-K Other Events
Item 8.01 Other Events.
On May25, 2017, Trovagene,Inc. issued a press release announcing
summary data from a phase 1 safety study conducted by Nerviano
Medical Sciences with PCM-075, a polo-like kinase 1 (PLK1)
inhibitor. This data is supportive of a planned phase 1/2
clinical trial in patients with acute myeloid leukemia (AML) and
is now being submitted for peer review publication by study
investigators. A copy of the press release is furnished as
Exhibit99.1 to this Form8-K.
Item 9.01. Financial Statements and Exhibits
|
(d) |
Exhibits. |
||
|
99.1 |
Press Release of Trovagene,Inc. dated May25, 2017 |
||
About Trovagene, Inc. (NASDAQ:TROV)
Trovagene, Inc. (TrovaGene) is a molecular diagnostic company. The Company focuses on the development and commercialization of a molecular diagnostic technology for use in disease detection and monitoring across a range of medical disciplines. Its primary internal focus is to leverage its cell-free molecular diagnostic platform to facilitate improvements in the field of oncology, while its external focus includes entering into license agreements or collaborations to develop its technology in areas, such as infectious disease, transplant medicine and prenatal genetics. It has ongoing clinical collaborations to demonstrate the ability to determine and monitor mutational status and response to therapy in lung, colon, pancreatic and skin cancer. It uses its molecular diagnostic technology for the detection of cell-free deoxyribonucleic acid (DNA) originating from diseased cell death that can be isolated and detected from urine, blood and tissue samples to develop disease management. Trovagene, Inc. (NASDAQ:TROV) Recent Trading Information
Trovagene, Inc. (NASDAQ:TROV) closed its last trading session up +0.037 at 0.759 with 107,080 shares trading hands.